Mechanotransduction in Cardiomyocyte Hypertrophy
2001; Lippincott Williams & Wilkins; Volume: 103; Issue: 10 Linguagem: Inglês
10.1161/01.cir.103.10.1375
ISSN1524-4539
Autores Tópico(s)Cardiac electrophysiology and arrhythmias
ResumoHomeCirculationVol. 103, No. 10Mechanotransduction in Cardiomyocyte Hypertrophy Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBMechanotransduction in Cardiomyocyte Hypertrophy Peter H. Sugden Peter H. SugdenPeter H. Sugden From the National Heart and Lung Institute Division, Imperial College School of Medicine, London, UK. Originally published13 Mar 2001https://doi.org/10.1161/01.CIR.103.10.1375Circulation. 2001;103:1375–1377The study of ventricular hypertrophy has recently been a fruitful research area. From studies principally in neonatal rat ventricular myocytes in primary culture but now increasingly in transgenic mice, the molecular mechanisms involved in this important pathophysiological adaptation are becoming clearer.1 In culture, cardiomyocyte hypertrophy is characterized by numerous transcriptional and morphological changes, including increased expression of atrial and B-type natriuretic peptides (ANP and BNP, respectively), increased β-myosin heavy chain (β-MHC) expression, and increased sarcomere deposition.1 Similar changes are evident in hypertrophied hearts in vivo, where increased sarcomere deposition in particular allows cardiomyocytes to accommodate demands for elevated contractile power.Wall Strain and Left Ventricular HypertrophyIn vivo, pathological or experimental left ventricular hemodynamic overload induces patterns of hypertrophy that can be broadly divided into concentric or eccentric. In concentric (pressure-overload) hypertrophy, peak-systolic and end-diastolic pressures are increased, but meridional ventricular wall stress is normal throughout the cardiac cycle, the additional wall stress being counterbalanced by wall thickening in the absence of chamber enlargement. In eccentric (volume-overload) hypertrophy, chamber volume is enlarged, and wall thickness is increased approximately in proportion to the increase in chamber diameter. End-diastolic pressure and wall stress are increased, but peak systolic pressure and wall stress are normal.The orientation of cardiomyocytes in heart is primarily circumferential. Thus, cardiomyocytes from pressure- or volume-overloaded hearts differ in their relative dimensions. Cross-sectional area is proportionally expanded over length in pressure overload, whereas length is proportionally increased in volume overload. Sarcomere deposition parallel to the long axes of cells is greater in pressure overload than in volume overload, in which deposition of sarcomeres in series predominates. Changes in gene and protein expression in vivo may not be identical in the 2 paradigms. One study showed that although increases in prepro-ANP mRNA are comparable, increases in β-MHC mRNA occur only in pressure overload2 (although others, using protein expression, have detected increases in β-MHC in both situations3 ).Cardiomyocyte culture models have provided little information about mechanisms underlying development of these distinct cellular morphologies or the signaling pathways responsible for the differences. The α-adrenergic agonist phenylephrine, which acts through G protein–coupled receptors (GPCRs), induces hypertrophy reminiscent of a pressure-overloaded cardiomyocyte, whereas the cytokine-related agonist cardiotrophin-1 produces a volume-overloaded morphology.4 To gain information about the differing responses to pressure overload and volume overload, Yamamoto et al,5 in this issue of Circulation, use cultured cardiomyocytes to focus on differences in intracellular signaling and gene expression induced by strain imposed specifically at the systolic and diastolic phases of the contractile cycle.Signal Transduction in Cardiac HypertrophyReversible protein phosphorylation and/or dephosphorylation play a central role in signal transduction in cardiomyocyte hypertrophy. Multiple signaling pathways probably mediate hypertrophy (particularly in vivo), with 2 important groups of regulatory proteins having been identified: the mitogen-activated protein kinases (MAPKs)1 and Ca2+/calmodulin-activated protein kinases/phosphatases.167 The latter include Ca2+/calmodulin-dependent protein kinases (CaM kinases) and calcineurin, but Yamamoto et al5 focused only on MAPK signaling. MAPKs are final members of 3-component protein kinase cascades in which a MAPK kinase kinase (MKKK) phosphorylates and activates a MAPK kinase (MKK), which finally phosphorylates and activates a MAPK.8 After their activation, MAPKs phosphorylate other signaling proteins (notably transcription factors and other protein kinases) to change their biological activities. Through these phosphorylations, MAPKs regulate cell growth and survival and other biological processes.The simplest subclassification of MAPKs into 3 subfamilies [extracellular-signal–regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38-MAPKs] is based on the primary sequence of their phosphorylation motifs. p42/p44-MAPKs (ERK2 and ERK1, respectively) were the first to be identified and remain the best characterized, being strongly stimulated by growth-promoting stimuli in all cells. In cardiomyocytes, they are powerfully activated by hypertrophic agonists that couple to GPCRs of the Gq-coupled subclass.1 These include phenylephrine, endothelin-1 (ET-1), and angiotensin II (Ang II). The linkage between GqPCR activation and stimulation of the p42/p44-MAPK cascade is unclear. It probably involves the phospholipase Cβ/protein kinase C pathway and activation of the 21-kDa GTPase Ras.1 This last step leads to activation of the Raf MKKKs, thence to MEK1/2 (the MKKKs and MKKs of the p42/p44-MAPK cascade) and p42/p44-MAPK.18 Three other ERK subfamily members have been identified, the poorly characterized ERK3, ERK5 [or "big" (≈100-kDa) MAPK, BMK1], and the recently identified ERK7. PD98059 and U0126 inhibit activation of p42/p44-MAPK (and BMK1) by inhibiting at the MKKK/MKK levels and have proved useful in identifying ERK-dependent responses.JNKs and p38-MAPKs are more strongly activated by cytotoxic cellular stresses (reactive oxygen species, hyperosmotic stress, anisomycin, ischemia/reperfusion) than by ET-1 or phenylephrine in cardiomyocytes or isolated hearts.9 In humans, mRNAs transcribed from 3 JNK genes are alternatively spliced, producing 10 JNK isoforms with molecular masses of either ≈46 or ≈54 kDa. p38-MAPKs (α, β, γ, and δ isoforms) are encoded by 4 genes, with the α- and β-isoforms each being alternatively spliced. SB203580 (<1 μmol/mL) directly and reversibly inhibits activated p38-MAPKα/β2 (but does not inhibit p38-MAPKγ/δ) and is useful in implicating p38-MAPKα/β2 in biological processes. Although this is still controversial, all 3 MAPK subfamilies have been associated with hypertrophic signaling,1 although a view exists that JNKs and p38-MAPKα may be detrimental to cardiomyocyte survival.1 I have emphasized the primacy of p42/p44-MAPK activation in compensated hypertrophy, with JNKs and p38-MAPKs possibly more involved in development/maintenance of decompensated states. Recent work in transgenic mice supports this.10Mechanical Strain and Signal TransductionAlthough the terms "stress" and "strain" are used interchangeably, they have different physical meanings. Stress is a force that induces strain, which is the change in shape or the deformation produced. Static or intermittent stress/strain of cultured cardiomyocytes on deformable Silastic membranes induces many of the transcriptional and signaling responses of hypertrophy (including activation of MAPKs).111 Such findings may be relevant to mechanotransduction (the coupling of mechanical forces on cells to biological responses) in hemodynamic overload in vivo. Yamamoto et al5 refined the mechanical deformational model to examine differences in intracellular signaling and gene expression induced by spatially isotropic (ie, uniform) biaxial strain imposed at the systolic (see pressure overload in vivo) or diastolic (see volume overload) phase of the contractile cycle in electrically paced cardiomyocytes. Control experiments involved strain/no pacing or pacing/no strain. (Note that these strained/unpaced cardiomyocytes still contract spontaneously but at a lower frequency than paced cells. Contraction is therefore out of phase with strain.)Using antibodies specific for phosphorylated (activated) MAPKs, Yamamoto et al5 showed that systolic strain increased p42/p44-MAPK phosphorylation by up to 10-fold. This increase was significantly greater than those elicited by strain/no pacing or pacing/no strain (≈2- to 3-fold). The increase in p42/p44-MAPK phosphorylation with diastolic strain was intermediate, being at most ≈6-fold. Likewise, differential phosphorylation of MEK1/2 was demonstrable. PD98059 completely inhibited systolic strain–induced phosphorylation of p42/p44-MAPK. Although p38-MAPKs and JNKs were also phosphorylated (maximally ≈3- and ≈6-fold, respectively) with systolic or diastolic strain, there were no detectable differences in the extent of phosphorylation between the 2 conditions. p38-MAPKs (but not JNKs) were also phosphorylated in strained/unpaced or paced/unstrained cardiomyocytes. These results imply that the p42/p44-MAPK cascade (but not the JNK or p38-MAPK cascade) responds differentially to cardiac cycle phase–specific strains.BNP mRNA was rapidly induced by systolic strain (≈6-fold) and diastolic strain (≈3-fold), although only the former was significantly greater than in strained/unpaced or paced/unstrained cardiomyocytes.5 Systolic strain was more effective in inducing mRNA encoding the extracellular matrix protein tenascin C. Although this was not quantified, the authors suggest that BNP mRNA induction by systolic strain was essentially completely inhibited by PD98059. In contrast, SB203580 appeared to be less effective, although the absence of accurate quantification of blots to take into account the 18S rRNA loading control makes this difficult to assess unambiguously. Finally, systolic strain for 1 hour was more effective in increasing leucine incorporation into protein over the subsequent 24 hours than other treatments, although these also significantly stimulated leucine incorporation. Because leucine incorporation was measured over a prolonged period, such incorporation will reflect both the total protein pool (equilibrium labeling) and the initial rate of protein synthesis. Its physical significance (total protein versus initial rate) is therefore difficult to assess. PD98059 (present throughout the incubation) inhibited leucine incorporation by ≈60%, suggesting that activation of p42/p44-MAPKs may be responsible. Inhibition (≈30%) by SB203580 was not statistically significant. Because of the possible role of tonic p42/p44-MAPK activity in cell survival, prolonged exposure of cells to PD98059 may reduce viability. Indeed, PD98059 alone increases TUNEL-positivity and DNA laddering in cardiomyocytes.12 Experiments involving prolonged use of PD98059 should thus be interpreted cautiously.The overall conclusions of Yamamoto et al5 are that systolic strain is more effective than diastolic strain in activating the p42/p44-MAPK cascade and in stimulating expression of BNP and protein synthesis. This may be due to the sensitivity of cardiomyocytes to strain energy. Cell stiffness is greater during systole than diastole, and hence, systolic strain may deliver more strain energy. Such considerations, however, still do not identify the molecular events responsible for the differential responses.Mechanotransduction-Sensing MechanismsAlthough the sensor mechanisms for strain are unclear, they must be differentially affected by cardiac cycle phase–specific strain to account for the findings of Yamamoto et al.5 Information here is sparse. In studies of static strain, use of receptor antagonists suggests the autocrine/paracrine involvement of Ang II or ET-1 and MAPKs.1113 Whenever strain is mentioned, the nebulous entity of the mechanosensitive ion channel is invoked.14 These are cation-selective channels (but are not particularly selective for individual biological cations), which are often sensitive to inhibition by Gd3+ or streptomycin. Hypertrophic changes in statically strained cardiomyocytes, however, are not sensitive to Gd3+.11 Strain stimulates release of the prostanoid precursor arachidonate,11 possibly through MAPK-mediated activation of phospholipase A2. Prostaglandin F2α is reportedly hypertrophic in cardiomyocytes,1 but signal transduction here may involve JNKs rather than p42/p44-MAPKs.15 Extracellular matrix– (integrin-) based signaling could be involved,11 and signaling through Ca2+ (which could promote hypertrophy through CaM kinases or calcineurin67 ) cannot be excluded.Reactive oxygen species are increasingly recognized to be signaling molecules in their own right (especially at low concentrations), and they certainly activate MAPKs in cardiomyocytes.16 They inhibit protein synthesis, however, and are demonstrably apoptotic at higher concentrations.1718 The earlier experiments of Yamamoto and colleagues19 suggested that biaxial strain produces reactive oxygen species, which are responsible for induction of tenascin C mRNA through the transcription factor NF-κB. In contrast, induction of BNP mRNA is sensitive to Ang II AT1 receptor antagonists.19 Conversely, others have shown that BNP expression in strained cardiomyocytes is regulated by p38-MAPKs and NF-κB.20 Whether any of the changes induced by phasic strain are inhibited by antioxidants, calmodulin-directed inhibitors, or receptor and integrin antagonists should be examined. Whether systolic and diastolic strains produce morphologically distinct responses in cardiomyocytes needs to be established before data are extrapolated too widely. If prolonged strain is necessary for such changes to be apparent, this experiment may not be trivial, because cardiomyocytes are unlikely to remain attached to the substrate.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Peter H. Sugden, DPhil, NHLI Division (Cardiac Medicine), Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK. E-mail [email protected] References 1 Sugden PH, Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med.1998; 76:725–746.CrossrefMedlineGoogle Scholar2 Calderone A, Takahashi N, Izzo NJ Jr, et al. Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factor mRNAs. Circulation.1995; 92:2385–2390.CrossrefMedlineGoogle Scholar3 Dool JS, Mak AS, Friberg P, et al. Regional myosin heavy chain expression in volume and pressure overload induced hypertrophy. Acta Physiol Scand.1995; 155:396–404.MedlineGoogle Scholar4 Wollert KC, Taga T, Saito M, et al. Cardiotrophin-1 activates a distinct form of cardiac hypertrophy: assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem.1996; 271:9535–9545.CrossrefMedlineGoogle Scholar5 Yamamoto K, Dang QN, Maeda Y, et al. Regulation of cardiomyocyte mechanotransduction by the cardiac cycle. Circulation.2001; 103:1459–1464.CrossrefMedlineGoogle Scholar6 Molkentin JD, Lu J-R, Antos C, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell.1998; 93:215–228.CrossrefMedlineGoogle Scholar7 Passier R, Zeng H, Frey N, et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest.2000; 105:1395–1406.CrossrefMedlineGoogle Scholar8 Cohen P. The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol.1997; 7:353–361.CrossrefMedlineGoogle Scholar9 Sugden PH, Clerk A. "Stress-responsive" mitogen-activated protein kinases in the myocardium. Circ Res.1998; 83:345–352.CrossrefMedlineGoogle Scholar10 Bueno OF, de Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated hypertrophy in transgenic mice. EMBO J.2000; 19:6341–6350.CrossrefMedlineGoogle Scholar11 Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol.1997; 59:551–571.CrossrefMedlineGoogle Scholar12 Aikawa R, Komuro I, Yamazaki T, et al. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest.1997; 100:1813–1821.CrossrefMedlineGoogle Scholar13 Yamazaki T, Komuro I, Kudoh S, et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem.1996; 271:3221–3228.CrossrefMedlineGoogle Scholar14 Hu H, Sachs F. Stretch-activated ion channels in the heart. J Mol Cell Cardiol.1997; 29:1511–1523.CrossrefMedlineGoogle Scholar15 Adams JW, Sah VP, Henderson SA, et al. Tyrosine kinase and c-Jun NH2-terminal kinase mediate hypertrophic responses to prostaglandin F2α in cultured neonatal rat ventricular myocytes. Circ Res.1998; 83:167–178.CrossrefMedlineGoogle Scholar16 Clerk A, Michael A, Sugden PH. Stimulation of multiple mitogen-activated protein kinase sub-families by oxidative stress and phosphorylation of the small heat shock protein, HSP25/27, in neonatal ventricular myocytes. Biochem J.1998; 333:581–589.CrossrefMedlineGoogle Scholar17 Cook SA, Sugden PH, Clerk A. Regulation of Bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. Circ Res.1999; 85:940–949.CrossrefMedlineGoogle Scholar18 Pham FH, Sugden PH, Clerk A. Regulation of protein kinase B and 4E-BP1 by oxidative stress in cardiac myocytes. Circ Res.2000; 86:1252–1258.CrossrefMedlineGoogle Scholar19 Yamamoto K, Dang QN, Kennedy SP, et al. Induction of tenascin-C in cardiac myocytes by mechanical deformation: role of reactive oxygen species. J Biol Chem.1999; 274:21840–21846.CrossrefMedlineGoogle Scholar20 Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-κB-dependent mechanism. J Clin Invest.1999; 104:1603–1612.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Chen D, Li Z, Bao P, Chen M, Zhang M, Yan F, Xu Y, Ji C, Hu X, Sanchis D, Zhang Y and Ye J (2019) Nrf2 deficiency aggravates Angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6/STAT3-dependent inflammation, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 10.1016/j.bbadis.2019.01.020, 1865:6, (1253-1264), Online publication date: 1-Jun-2019. Karamlou T, Giraud G, McKeogh D, Jonker S, Shen I, Ungerleider R and Thornburg K (2019) Right ventricular remodeling in response to volume overload in fetal sheep, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00439.2018, 316:5, (H985-H991), Online publication date: 1-May-2019. Yang T, Liu T, Cao C and Xu S (2018) miR‐200a‐5p augments cardiomyocyte hypertrophy induced by glucose metabolism disorder via the regulation of selenoproteins, Journal of Cellular Physiology, 10.1002/jcp.27206, 234:4, (4095-4103), Online publication date: 1-Apr-2019. Cheng Z, Zhang M, Hu J, Lin J, Feng X, Wang S, Wang T, Gao E, Wang H and Sun D (2018) Mst1 knockout enhances cardiomyocyte autophagic flux to alleviate angiotensin II-induced cardiac injury independent of angiotensin II receptors, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2018.08.028, 125, (117-128), Online publication date: 1-Dec-2018. Ma S and Vunjak-Novakovic G (2016) Tissue-Engineering for the Study of Cardiac Biomechanics, Journal of Biomechanical Engineering, 10.1115/1.4032355, 138:2, Online publication date: 1-Feb-2016. Khan A, Sheikh M, Kaw D, Cooper C and Khouri S (2014) Prevalence and factors associated with left ventricular remodeling in renal artery stenosis, Journal of the American Society of Hypertension, 10.1016/j.jash.2014.01.008, 8:4, (254-261), Online publication date: 1-Apr-2014. Alsaad A, Zordoky B, Tse M and El-Kadi A (2013) Role of cytochrome P450–mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy, Drug Metabolism Reviews, 10.3109/03602532.2012.754460, 45:2, (173-195), Online publication date: 1-May-2013. Onitsuka K, Ide T, Arai S, Hata Y, Murayama Y, Hosokawa K, Sakamoto T, Tobushi T, Sakamoto K, Fujino T and Sunagawa K (2013) Cardiac phase-targeted dynamic load on left ventricle differentially regulates phase-sensitive gene expressions and pathway activation, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2013.08.008, 64, (30-38), Online publication date: 1-Nov-2013. Anand I and Florea V (2011) Alterations in Ventricular Structure Heart Failure: A Companion to Braunwald's Heart Disease, 10.1016/B978-1-4160-5895-3.10015-4, (232-253), . Minegishi S, Kitahori K, Murakami A and Ono M (2011) Mechanism of Pressure-Overload Right Ventricular Hypertrophy in Infant Rabbits, International Heart Journal, 10.1536/ihj.52.56, 52:1, (56-60), . Georgiopoulou V, Kalogeropoulos A, Raggi P and Butler J (2010) Prevention, Diagnosis, and Treatment of Hypertensive Heart Disease, Cardiology Clinics, 10.1016/j.ccl.2010.07.005, 28:4, (675-691), Online publication date: 1-Nov-2010. Vahtola E, Louhelainen M, Forstén H, Merasto S, Raivio J, Kaheinen P, Kytö V, Tikkanen I, Levijoki J and Mervaala E (2010) Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat, Cardiovascular Diabetology, 10.1186/1475-2840-9-5, 9:1, Online publication date: 1-Dec-2010. Mohamed J, Lopez M and Boriek A (2010) Mechanical Stretch Up-regulates MicroRNA-26a and Induces Human Airway Smooth Muscle Hypertrophy by Suppressing Glycogen Synthase Kinase-3β, Journal of Biological Chemistry, 10.1074/jbc.M110.101147, 285:38, (29336-29347), Online publication date: 1-Sep-2010. Pagourelias E, Giannoglou G, Kouidi E, Efthimiadis G, Zorou P, Tziomalos K, Karagiannis A, Athyros V, Geleris P and Mikhailidis D (2010) Brain natriuretic peptide and the athlete's heart: a pilot study, International Journal of Clinical Practice, 10.1111/j.1742-1241.2009.02184.x, 64:4, (511-517), Online publication date: 1-Mar-2010. Subramaniam V and Lip G (2014) Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke, Expert Review of Cardiovascular Therapy, 10.1586/erc.09.43, 7:6, (703-713), Online publication date: 1-Jun-2009. Qian H and Elson E (2010) Chemical Fluxes in Cellular Steady States Measured by Fluorescence Correlation Spectroscopy Single Molecule Spectroscopy in Chemistry, Physics and Biology, 10.1007/978-3-642-02597-6_6, (119-137), . Osorio J, Cheema F, Martens T, Mahmut N, Kinnear C, Gonzalez A, Bonney W, Homma S, Liao J and Mital S (2008) Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptorPresented in part at the American College of Cardiology meeting March 2003 in Orlando, USA, and the Society for Pediatric Research meeting May 2007 in Toronto, Canada., Canadian Journal of Physiology and Pharmacology, 10.1139/Y08-068, 86:9, (633-642), Online publication date: 1-Sep-2008. Soppa G, Barton P, Terracciano C and Yacoub M (2008) Left ventricular assist device-induced molecular changes in the failing myocardium, Current Opinion in Cardiology, 10.1097/HCO.0b013e3282fc7010, 23:3, (206-218), Online publication date: 1-May-2008. Gonzalez A, Osorio J, Manlhiot C, Gruber D, Homma S and Mital S (2007) Hypertrophy signaling during peripartum cardiac remodeling, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00401.2007, 293:5, (H3008-H3013), Online publication date: 1-Nov-2007. Omens J, McCulloch A and Lorenzen-Schmidt I Mechanotransduction in Cardiac Remodeling and Heart Failure Cardiac Mechanotransduction, 10.1007/978-0-387-48868-4_5, (78-92) Opie L, Commerford P, Gersh B and Pfeffer M (2006) Controversies in ventricular remodelling, The Lancet, 10.1016/S0140-6736(06)68074-4, 367:9507, (356-367), Online publication date: 1-Jan-2006. Tual L, Morel O, Favret F, Fouillit M, Guernier C, Buvry A, Germain L, Dhonneur G, Bernaudin J and Richalet J (2006) Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia, Pflügers Archiv - European Journal of Physiology, 10.1007/s00424-006-0058-5, 452:4, (371-379), Online publication date: 1-Jul-2006. Tanaka Y, Tamura K, Koide Y, Sakai M, Tsurumi Y, Noda Y, Umemura M, Ishigami T, Uchino K, Kimura K, Horiuchi M and Umemura S (2005) The novel angiotensin II type 1 receptor (AT1R)-associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy, FEBS Letters, 10.1016/j.febslet.2005.01.068, 579:7, (1579-1586), Online publication date: 14-Mar-2005. Gopalan S, Flaim C, Bhatia S, Hoshijima M, Knoell R, Chien K, Omens J and McCulloch A (2003) Anisotropic stretch-induced hypertrophy in neonatal ventricular myocytes micropatterned on deformable elastomers, Biotechnology and Bioengineering, 10.1002/bit.10506, 81:5, (578-587), Online publication date: 5-Mar-2003. Periasamy M (2002) Calcineurin and the Heartbeat, an Evolving Story, Journal of Molecular and Cellular Cardiology, 10.1006/jmcc.2001.1520, 34:3, (259-262), Online publication date: 1-Mar-2002. Rabkin E and Schoen F (2002) Cardiovascular tissue engineering, Cardiovascular Pathology, 10.1016/S1054-8807(02)00130-8, 11:6, (305-317), Online publication date: 1-Nov-2002. Frias M, Somers S, Gerber-Wicht C, Opie L, Lecour S and Lang U (2008) The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis, Cardiovascular Research, 10.1093/cvr/cvn171, 80:1, (69-77) March 13, 2001Vol 103, Issue 10 Advertisement Article InformationMetrics Copyright © 2001 by American Heart Associationhttps://doi.org/10.1161/01.CIR.103.10.1375 Originally publishedMarch 13, 2001 KeywordshypertrophymyocytesEditorialssignal transductionPDF download Advertisement
Referência(s)